GlobeNewswire: Veru Inc. Contains the last 10 of 275 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T21:53:23ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/22/2851138/0/en/Veru-Reschedules-Annual-Meeting-of-Shareholders.html?f=22&fvtc=4&fvtv=10233Veru Reschedules Annual Meeting of Shareholders2024-03-22T20:05:00Z<![CDATA[--Restated historical financial statements expected to be filed no later than April 15, 2024----2024 Annual Meeting of Shareholders to follow financial statements filings--]]>https://www.globenewswire.com/news-release/2024/03/12/2844447/0/en/Veru-Announces-the-Appointment-of-Louis-Aronne-MD-as-Chief-Medical-Advisor-for-its-Enobosarm-Program-for-High-Quality-Weight-Loss.html?f=22&fvtc=4&fvtv=10233Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss2024-03-12T12:00:00Z<![CDATA[MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announced the appointment of Louis Aronne, MD, as Chief Medical Advisor and a member of the Scientific Advisory Board to support the advancement of enobosarm, an oral novel selective androgen receptor modulator (SARM), to avoid muscle loss and augment fat loss when combined with a Glucagon-like peptide-1 receptor agonist (GLP-1 RA) drug for potentially higher quality weight loss.]]>https://www.globenewswire.com/news-release/2024/02/28/2836552/0/en/Veru-Announces-Notification-from-Nasdaq-Related-to-Delayed-Quarterly-Report-on-Form-10-Q.html?f=22&fvtc=4&fvtv=10233Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q2024-02-28T00:15:00Z<![CDATA[MIAMI, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announced that it received a delinquency notification letter (“Notice”) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) on February 21, 2024 due to the Company’s non-compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023 (the “Form 10-Q”). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “SEC”).]]>https://www.globenewswire.com/news-release/2024/02/20/2831853/0/en/Veru-Announces-New-Scientific-Advisory-Board-for-its-Enobosarm-Program-for-High-Quality-Weight-Loss.html?f=22&fvtc=4&fvtv=10233Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss2024-02-20T13:30:00Z<![CDATA[MIAMI, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announced the formation of a new Scientific Advisory Board to support the advancement of enobosarm, an oral novel selective androgen receptor modulator (SARM), to avoid muscle loss and augment fat loss when combined with a Glucagon-like peptide-1 receptor agonist (GLP-1 RA) drugs for potentially higher quality weight loss. The Scientific Advisory Board brings deep and complementary knowledge in metabolic diseases, obesity, weight management, muscle preservation and physical function in addition to significant experience in clinical research and in drug development.]]>https://www.globenewswire.com/news-release/2024/02/08/2825838/0/en/Veru-Reports-Fiscal-2024-First-Quarter-Financial-Highlights.html?f=22&fvtc=4&fvtv=10233Veru Reports Fiscal 2024 First Quarter Financial Highlights2024-02-08T11:30:00Z<![CDATA[—Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone—]]>https://www.globenewswire.com/news-release/2024/02/06/2824317/0/en/Veru-Announces-FDA-Clearance-of-IND-Application-to-Initiate-Phase-2b-Clinical-Trial-with-Enobosarm-to-Treat-Muscle-Loss-Associated-with-Weight-Loss-Drugs.html?f=22&fvtc=4&fvtv=10233Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs2024-02-06T13:30:00Z<![CDATA[FDA IND clearance is an important development milestone in advancing enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone]]>https://www.globenewswire.com/news-release/2024/01/31/2821132/0/en/Veru-to-Present-at-the-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html?f=22&fvtc=4&fvtv=10233Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference2024-01-31T13:30:00Z<![CDATA[MIAMI, FL, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for obesity, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present an update of Veru’s Phase 2b clinical program of enobosarm to augment fat loss and to avoid muscle loss when combined with GLP-1 drugs for weight loss at the upcoming virtual Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024 at 12:40 pm – 1:10 pm ET.]]>https://www.globenewswire.com/news-release/2024/01/25/2816780/0/en/Veru-to-Report-Fiscal-2024-First-Quarter-Financial-Results-on-February-8-2024.html?f=22&fvtc=4&fvtv=10233Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 20242024-01-25T13:30:00Z<![CDATA[MIAMI, FL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and viral induced acute respiratory distress syndrome, today announced it will host a conference call and audio webcast on Thursday, February 8, 2024, at 8:00 a.m. ET to discuss its fiscal 2024 first quarter financial results and to provide a business update.]]>https://www.globenewswire.com/news-release/2024/01/08/2805447/0/en/Veru-Submits-IND-Application-to-FDA-for-the-Development-of-Enobosarm-to-Prevent-Muscle-Loss-While-Augmenting-Fat-Loss-in-Combination-with-GLP-1-Drugs-for-Weight-Loss.html?f=22&fvtc=4&fvtv=10233Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss2024-01-08T13:30:00Z<![CDATA[MIAMI, FL, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and viral induced acute respiratory distress syndrome, today announced submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for the development of enobosarm for obesity.]]>https://www.globenewswire.com/news-release/2023/12/19/2798523/0/en/Veru-to-Host-Investor-Call-on-January-4th-2024-to-Discuss-Recent-Financing-and-Strategy-to-Prioritize-the-Development-of-Enobosarm-as-a-Combination-Treatment-to-Prevent-Muscle-Loss.html?f=22&fvtc=4&fvtv=10233Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs2023-12-19T13:30:00Z<![CDATA[MIAMI, FL, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and viral induced acute respiratory distress syndrome, today announced it will host an investor conference call and audio webcast on Thursday, January 4, 2024, at 8:00 a.m. ET to discuss the recent financing and the Company’s strategy to prioritize the development of enobosarm for weight loss as well as provide an update on the Company’s drug pipeline.]]>